CL2021003039A1 - Moléculas de unión a tigit y pd-1/tigit - Google Patents

Moléculas de unión a tigit y pd-1/tigit

Info

Publication number
CL2021003039A1
CL2021003039A1 CL2021003039A CL2021003039A CL2021003039A1 CL 2021003039 A1 CL2021003039 A1 CL 2021003039A1 CL 2021003039 A CL2021003039 A CL 2021003039A CL 2021003039 A CL2021003039 A CL 2021003039A CL 2021003039 A1 CL2021003039 A1 CL 2021003039A1
Authority
CL
Chile
Prior art keywords
tigit
binding molecules
chemotherapy
human
binding polypeptide
Prior art date
Application number
CL2021003039A
Other languages
English (en)
Inventor
Stephanie Marie Truhlar
Yiqing Feng
James David Pancook
Naresh Kumar
Yang Zhao
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2021003039A1 publication Critical patent/CL2021003039A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a las moléculas de polipéptidos que se unen a TIGIT humano, y a las moléculas de polipéptidos que se unen a PD-1 humano y a TIGIT humano, y son útiles para tratar tumores sólidos, solas y en combinación con quimioterapia y/o radiación ionizante.
CL2021003039A 2019-05-29 2021-11-17 Moléculas de unión a tigit y pd-1/tigit CL2021003039A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962853816P 2019-05-29 2019-05-29

Publications (1)

Publication Number Publication Date
CL2021003039A1 true CL2021003039A1 (es) 2022-08-05

Family

ID=71070067

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003039A CL2021003039A1 (es) 2019-05-29 2021-11-17 Moléculas de unión a tigit y pd-1/tigit

Country Status (24)

Country Link
US (1) US20220227860A1 (es)
EP (1) EP3976652A1 (es)
JP (2) JP7241207B2 (es)
KR (1) KR20220004120A (es)
CN (1) CN113939536B (es)
AR (1) AR118980A1 (es)
AU (1) AU2020283817A1 (es)
BR (1) BR112021021795A2 (es)
CA (1) CA3139025A1 (es)
CL (1) CL2021003039A1 (es)
CO (1) CO2021015610A2 (es)
CR (1) CR20210573A (es)
DO (1) DOP2021000241A (es)
EA (1) EA202192796A1 (es)
EC (1) ECSP21085693A (es)
IL (1) IL287765A (es)
JO (1) JOP20210314A1 (es)
MA (1) MA56029A (es)
MX (1) MX2021014472A (es)
PE (1) PE20220505A1 (es)
PH (1) PH12021552970A1 (es)
SG (1) SG11202112725XA (es)
TW (1) TWI760751B (es)
WO (1) WO2020242919A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
LT3565579T (lt) 2017-01-05 2023-09-11 Kahr Medical Ltd. Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai
PT3565828T (pt) 2017-01-05 2022-02-08 Kahr Medical Ltd Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
US12134638B2 (en) 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
KR20210044221A (ko) 2018-07-11 2021-04-22 카 메디컬 리미티드 Pd1-4-1bbl 변이체 융합 단백질 및 이의 사용 방법
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
US20240076346A1 (en) * 2021-01-13 2024-03-07 Kahr Medical Ltd. Type i membrane proteins heterodimers and methods of use thereof
BR112023020193A2 (pt) * 2021-04-30 2023-11-14 Medimmune Llc Proteína de ligação biespecífica, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, anticorpo biespecífico, métodos para tratamento ou prevenção de câncer e para intensificar uma resposta imunológica, e, usos de uma proteína de ligação biespecífica e de um ácido nucleico
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
TW202327610A (zh) * 2021-08-30 2023-07-16 美商G1治療公司 具有檢查點抑制劑抗性或抗性易感性之晚期性/轉移性癌症之改良治療
TW202337897A (zh) * 2021-11-18 2023-10-01 大陸商信達生物製藥（蘇州）有限公司 抗ｐｄ－１抗體和抗ｖｅｇｆ－ａ抗體的藥物組合及其使用方法
CA3256561A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and their uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916681A1 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
SG11201700258VA (en) 2014-07-16 2017-02-27 Genentech Inc Methods of treating cancer using tigit inhibitors and anti-cancer agents
AU2015305754B2 (en) 2014-08-19 2018-10-25 Merck Sharp & Dohme Llc Anti-tigit antibodies
CN107207594B (zh) 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
CA2994858C (en) 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
CN110088132B (zh) 2016-08-17 2020-10-27 康姆普根有限公司 抗tigit抗体，抗pvrig抗体及其组合
JOP20190133A1 (ar) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
RS64576B1 (sr) * 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
AR112603A1 (es) * 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
TW201930358A (zh) * 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之單域抗體及其變異體
CN112739717B (zh) * 2018-06-29 2025-02-11 璟尚生物制药公司 三特异性拮抗剂

Also Published As

Publication number Publication date
CN113939536A (zh) 2022-01-14
EP3976652A1 (en) 2022-04-06
KR20220004120A (ko) 2022-01-11
PE20220505A1 (es) 2022-04-07
JOP20210314A1 (ar) 2023-01-30
CA3139025A1 (en) 2020-12-03
MX2021014472A (es) 2022-01-06
CO2021015610A2 (es) 2021-11-30
ECSP21085693A (es) 2021-12-30
PH12021552970A1 (en) 2022-07-25
JP2023071889A (ja) 2023-05-23
US20220227860A1 (en) 2022-07-21
DOP2021000241A (es) 2021-12-30
TW202110884A (zh) 2021-03-16
AR118980A1 (es) 2021-11-17
IL287765A (en) 2022-01-01
EA202192796A1 (ru) 2022-03-03
TWI760751B (zh) 2022-04-11
WO2020242919A1 (en) 2020-12-03
CR20210573A (es) 2021-12-15
AU2020283817A1 (en) 2021-11-25
MA56029A (fr) 2022-04-06
SG11202112725XA (en) 2021-12-30
CN113939536B (zh) 2024-05-14
BR112021021795A2 (pt) 2022-01-04
JP7241207B2 (ja) 2023-03-16
JP2022533457A (ja) 2022-07-22

Similar Documents

Publication Publication Date Title
CL2021003039A1 (es) Moléculas de unión a tigit y pd-1/tigit
CR20230477A (es) MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593)
ECSP19013181A (es) Anticuerpos de anti-tim-3
CY1124955T1 (el) Pd-1 αντισωματα
ECSP20007663A (es) Anticuerpos anti-cd137
CL2019001459A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1.
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
EP4219559A3 (en) Antibodies for lilrb2
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
CO2018002009A2 (es) Anticuerpos que se unen al ligando 1 de muerte celular programada 1 humana (pd-l1)
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
ECSP21026021A (es) Moduladores de la expresión de pnpla3
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
MX2020006297A (es) Variantes de cd19.
UY38472A (es) Moduladores de la expresión de foxp3
MX2020009863A (es) Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-l1.
AR117079A1 (es) Moduladores de la expresión de foxp3
AR119639A1 (es) Moléculas de anticuerpo para cd73 y sus usos